Actively Recruiting
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Led by Sun Yat-sen University · Updated on 2023-08-29
300
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying pituitary neuroendocrine tumors, which can be resistant to usual treatments like surgery, drug therapy, and radiotherapy. These tumors may relapse or regrow early after surgery and have a poor outlook. The study aims to find molecular markers in blood or tissue, along with imaging features, that can predict how invasive the tumor is and its likely progression or recurrence after treatment. Participants diagnosed with pituitary neuroendocrine tumors through clinical imaging, with or without hormone secretion confirmed by hormone tests, will be observed. They will be treated according to established clinical guidelines and pathways. The study will collect clinical data and biological samples to track changes in biomarkers and imaging features during disease progression and treatment. Participants will be monitored for up to five years after treatment to observe disease progression or recurrence. Researchers will analyze serum and tissue markers and imaging results to understand tumor behavior and prognosis. This observational study involves no experimental treatments but follows patients receiving standard care to learn more about predicting tumor outcomes.
CONDITIONS
Brief Title
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 70 years
- Diagnosed with pituitary neuroendocrine tumors by clinical imaging
- Pituitary hormone secretion function may be present or absent as confirmed by hormone detection
You will not qualify if you...
- Previous pathology indicating pituitary carcinoma
- Prior radiation, chemotherapy, immunotherapy, or targeted therapy
- Known genetic syndromes causing excessive hormone secretion (e.g., Carney syndrome, McCune-Albright syndrome, multiple endocrine neoplasia type 1)
- Presence of ectopic neuroendocrine tumors
- Major surgery within one month before screening or sphenoid pituitary surgery within three months before screening
- Crisis of gland function such as pituitary, thyroid, or adrenal crisis
- Severe diseases of peripheral glands, solid tumors, or blood system disorders
- Serious organ damage including heart, kidney, or liver
- Severe mental or nervous system diseases
- Serious high blood glucose, poorly controlled hypertension, or emergency conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 month
Participants undergo clinical imaging and pituitary hormone detection to diagnose pituitary neuroendocrine tumors.
1 to 2 visits depending on diagnostic procedures
Duration - Up to 5 years
Participants who have been diagnosed and treated according to clinical guidelines are observed for disease progression or recurrence after surgery.
Periodic visits during the 5-year follow-up period
Trial Site Locations
Total: 1 location
1
endocrinology department of the first affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here